Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 with Docetaxel and Prednisone in HRPC
NCT00571675Phase 2Completed
- Sponsor
- Ascenta Therapeutics
- Start
- Oct 2007
- Primary completion
- Sep 2010
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing AT-101 + Docetaxel + Prednisone with Placebo + Docetaxel + Prednisone (2 arms). Primary endpoint: Overall Survival at 33 months. Started Oct 2007; status: completed.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT00571675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571675.